Dr Simon ChenCataract & Retina Surgeon
Location
中文
For referrersRefer a patientRequest an appointment

Can eye floaters be treated without surgery?

For most people, the most effective non-surgical treatment for floaters is time: once an examination has shown the retina is healthy, floaters usually become much less noticeable over weeks to months. No supplement or eye drop has been shown to dissolve floaters. The supplement VitroCap N has one small positive trial, but that trial has important weaknesses and has not been repeated. Dilating eye drops can make floaters genuinely less visible, but in practice most people find the side effects outweigh the benefit.

Written by MBBS, BSc(Hons), FRANZCO

Cataract and retinal surgeon, Vision Eye Institute Chatswood, Sydney

Floaters are most noticeable against bright, plain backgrounds such as sky, a white page or a screen.

Will my floaters settle without treatment?

Usually, yes. Most troublesome floaters appear when the vitreous, the clear gel that fills the eye, shrinks and separates from the retina at the back of the eye. This is called a posterior vitreous detachment. The floaters it brings rarely vanish completely, but over time they tend to sink out of the centre of vision, and the brain learns to filter them out.

In Dr Chen's experience, most people with new floaters are much less troubled by them within about six weeks. There is no reliable study giving an exact percentage or timetable, which is why he generally suggests allowing three to six months before considering any procedure. A minority of people are still genuinely bothered by floaters after many months, and for them the effect on daily life can be real and significant.

ClearWith floaters
Move the slider to compare a clear scene with simulated floaters. This shows a symptom, not a treatment result.

This natural improvement matters when judging any treatment. If most people improve anyway, a treatment started soon after floaters appear will often seem to work, whether or not it has done anything.

How do the non-surgical options compare?

OptionWhat it doesStrength of evidenceMain drawbacks
Time and reassuranceFloaters settle lower in the eye and the brain adaptsConsistent clinical experience; no precise timetableSlow; some people remain bothered
VitroCap N supplementClaimed to protect the gel's structure; no established mechanismOne small trial with significant limitationsCost; months of use; unproven
Low-dose atropine dropsEnlarges the pupil a little so floater shadows are fainterSmall uncontrolled case series onlyGlare, blurred near vision; off-label in Australia
Standard dilating dropsEnlarges the pupil fullyOptics well understood; not a practical long-term optionLight sensitivity and loss of near focus for hours
Enzyme supplements (bromelain, papain)Claimed to break down floater clumpsOne unreplicated trialUnproven; can increase bleeding tendency
Sunglasses and other everyday measuresReduce how often floaters are noticedProfessional advice, not trialsOnly reduces awareness

Why do floaters bother some people more than others?

Floaters are small clumps and strands of collagen in the vitreous gel. You do not see the clumps themselves. You see their shadows, cast on the retina by the light passing through the pupil.

How noticeable a floater is depends on three things: its size, how close it lies to the retina, and the size of the pupil. A floater close to the retina casts a sharp, dark shadow. The pupil matters because it acts as the light source for the shadow. In bright light the pupil is small, light arrives through a narrow opening, and floater shadows are crisp and easy to see. This is why floaters are most obvious against a blue sky, a white wall or a bright screen, and why they fade in dim light.

This also explains why floaters that look minor during an examination can still be very bothersome, and why the brain's ability to ignore them varies so much from person to person. Floaters are associated with measurable anxiety for some people, and simply being reassured that the retina is healthy often helps more than any product.

What is VitroCap N and what is in it?

VitroCap N is an oral supplement sold in Australia for floaters. It was developed in Germany, and Dr Chen now sees many patients who have been advised to try it by their optometrist.

Supplements sold for floaters are taken daily for months. Only one, VitroCap N, has been tested in a placebo-controlled trial.

Each daily capsule contains:

IngredientAmount per capsule
L-lysine (an amino acid)125 mg
Vitamin C40 mg
Grape seed extract26.3 mg (25 mg proanthocyanidins)
Citrus bioflavonoids100 mg (60 mg hesperidin)
Zinc5 mg

The recommended course is one capsule a day with food for at least three to six months. At the time of writing it costs about $85 for a 90-day supply when bought online from the Australian distributor.

VitroCap N is a listed complementary medicine. Listed medicines may only contain ingredients the Therapeutic Goods Administration accepts as low risk, and the company certifies that the product meets the listing rules. The TGA does not assess a listed product before it goes on sale, and it does not assess whether it works.

The manufacturer suggests the ingredients protect the collagen and gel of the vitreous from age-related damage, through antioxidant effects and by reducing the chemical stiffening of collagen that comes with age. These ideas come from laboratory studies. There is no independent evidence that this combination, taken by mouth at these doses, changes the vitreous in people, and the trial researchers themselves did not measure whether the ingredients reached the eye. It is not obvious why this particular mix of ingredients was chosen.

What did the VitroCap N study find?

The main evidence is the FLIES trial, published in 2021. Sixty-one adults with floaters in Ireland were randomly given either the supplement or an identical dummy capsule for six months, without them or the researchers knowing which.

Among the 56 people who finished the study, those taking the supplement reported less discomfort from their floaters at the end than at the start, and in the 47 people whose photographs could be analysed, the total area of floaters was smaller. The placebo group improved only slightly: their average discomfort score fell a little, but not significantly, and their measured floater area rose slightly, also not significantly. Visual acuity did not change in either group. One of several contrast sensitivity measures improved slightly with the supplement.

Results reported by the FLIES trial for people who completed it (26 placebo, 30 supplement; floater area measured in 21 and 26). The placebo group improved only slightly and its measured floater area rose, though not significantly, which is unusual given how often floaters settle.

How much should the VitroCap N study be trusted?

Taken at face value the results are encouraging, but several features make them much less certain than the headline suggests.

  • Natural improvement was not accounted for. The study did not record how long people had had their floaters. Because new floaters usually settle on their own, the placebo group would be expected to improve noticeably too. It improved only slightly, which is surprising.
  • The main measure was a questionnaire written for this study and not tested elsewhere. The widely quoted figure of about two in three people benefiting was calculated by adding together changes in several answer categories, so the same person can be counted more than once. Calculated the same way, the placebo group's figure was about one in four.
  • Each group was mainly compared with itself. The conclusions rested on before-and-after comparisons within each group; the paper reports only one direct comparison between the groups, in its discussion rather than its results tables.
  • Floater areas were outlined by hand on photographs by a single researcher, one of the patent's named inventors, although they did not know which group each person was in.
  • It was small and has not been repeated. Only people who finished were analysed, and no independent trial has confirmed the result. Earlier supportive studies were uncontrolled or not blinded, and are mainly promoted by the manufacturer.
  • There are commercial links. The supplement's maker part funded the study and has a royalty agreement with the university, and two researchers, including the senior author, are named inventors on a pending patent for the formulation.

None of this proves the supplement does not work, but the evidence is weak and needs a larger independent trial.

Dr Chen's view. He remains sceptical. He has not seen a convincing explanation of how these ingredients would clear floaters, and suspects most of the benefit people notice reflects natural settling and the placebo effect; he would want people with long-standing floaters to report a clear benefit before recommending it. Even so, he mentions it as an option. It appears to be low risk, so if someone is happy to spend the money and try it for a few months, there is little harm, provided it does not replace an eye examination for new symptoms.

How do dilating eye drops make floaters less noticeable?

Drops that enlarge the pupil can make floaters much less visible. With a wide pupil, light reaches the retina from a broad cone of directions, so a floater blocks only part of it and its shadow becomes a faint, blurred patch instead of a small dark spot.

Small pupil (bright light)

Narrower light bundle: darker, sharper floater shadow (higher contrast)

Large pupil (dim light or dilating drops)

Broader light bundle: lighter, more diffuse floater shadow (lower contrast)

1 Floater2 Shadow on the retina3 Retinal view: what the shadow looks like
Light entering the eye is focused towards the retina. With a small pupil the narrow bundle is blocked completely by the floater, giving a dark, sharp shadow. With a large pupil the same floater blocks only part of a much wider cone, so its shadow is fainter and more diffuse.

The problem is the side effects. Full-strength dilating drops cause light sensitivity and glare, blurred vision, and, in people who have not had cataract surgery, loss of the eye's ability to focus up close for hours or days. Very few people tolerate this for long, so standard dilating drops are not a practical long-term treatment, even though they work well optically.

Can low-dose atropine drops help?

Low-dose atropine is an attempt to find a middle ground: a dose weak enough to be tolerable, but strong enough to widen the pupil a little and soften floater shadows. Atropine is usually used at 1% strength to dilate the pupil fully. The low doses used for floaters, typically 0.01%, are the same concentrations used to slow short-sightedness in children, where they widen the pupil by about half a millimetre on average in children. In young adults the effect can be larger: in one small study, a single 0.01% drop widened the pupil by more than a millimetre and reduced near focusing for about a day. Higher strengths such as 0.05% widen the pupil further, but reduce near focusing more.

Average effects of low-dose atropine on pupil size and near focusing after one year in a large trial in children with short-sightedness. Stronger drops widen the pupil more but also reduce near focusing. Adults were not studied.

The evidence for floaters is limited. The main published study, from a retina practice in the United States in 2025, looked back at 44 adults whose floaters had persisted for at least three months who were prescribed 0.01% atropine once a day. Only half used the drops for at least a week. Of those 22, 13 were satisfied and 11 wanted to continue, while about one in five reported worse near vision, and similar numbers reported worse distance vision or light sensitivity. There was no comparison group and follow-up was only one week, so a placebo effect cannot be excluded. A larger study led by the same investigator was registered in late 2023, again without a comparison group. Its status has not been updated since, and no results have been posted.

Some clinics overseas sell low-dose atropine specifically for floaters. A well-known example is a US floater practice that supplies custom-diluted atropine in several strengths after a telehealth consultation. In Australia, low-dose atropine is registered only for slowing myopia in children, so using it for floaters is off-label and needs a prescription; strengths outside the registered range need a compounding pharmacy.

It is most likely to be worth trying for someone who has already had cataract surgery, because their near focusing no longer depends on the natural lens. Younger people who still focus naturally are more likely to notice blurred reading vision. Any dilating drop can trigger acute angle-closure glaucoma in an eye with a narrow drainage angle, so the angle should be checked by an eye specialist before starting.

Do pineapple, bromelain or other enzyme supplements work?

Bromelain, an enzyme from pineapple, and papain, from papaya, can break down proteins, which is why they are promoted to "dissolve" floaters. A laboratory study found that enzymes, including bromelain, can partly reverse the light scattering caused by gel artificially aged with enzymes, but that was in pig vitreous in a dish.

Eyes whose ordinary floaters were reported as gone after three months, in the one trial of fruit enzyme capsules for floaters (results were weaker for floaters caused by bleeding). Only 2 of 40 eyes improved in the comparison group, which is unusually few. The result has not been repeated.

One trial from Taiwan in 2022 gave 160 people with ordinary floaters capsules of bromelain, papain and ficin at different doses for three months, and reported floaters disappearing in 55% to 70% of eyes, compared with 5% of eyes in the group given a vitamin C tablet instead. The result has not been repeated, the capsule was developed by the researchers themselves, and, as with VitroCap N, the near-absence of improvement in the comparison group is hard to reconcile with how often floaters settle naturally. There is no good evidence that eating pineapple helps.

Enzyme supplements such as bromelain and nattokinase can increase bleeding tendency, which matters for people taking blood thinners. There is no trial evidence for serrapeptase, hyaluronic acid, ginkgo, bilberry or other products sold as floater formulas.

Are there eye drops that dissolve floaters?

No. Drops applied to the surface of the eye cannot reach the vitreous in meaningful amounts to break up collagen clumps. Iodine-based drops have been used for floaters in some countries, but the supporting studies are decades old and poorly controlled. Other drops sold online for floaters have no reliable evidence, and some imported eye drops have been recalled or subject to regulatory warnings overseas because of contamination or unapproved claims. Unregulated eye drops can cause serious eye infections, so they are best avoided.

What helps day to day?

Simple measures reduce how often floaters catch your attention, even though they do not remove them.

Sunglasses soften glare and bright backgrounds, which makes floaters less noticeable outdoors.
  • Sunglasses or tinted lenses in bright light, which soften glare and bright backgrounds.
  • Avoiding very bright, plain backgrounds where possible, such as turning down screen brightness or using a darker screen theme if you find it helps.
  • Moving your eyes briefly up and down or side to side, which can shift a floater out of your line of sight for a while.
  • Not watching for them. The more attention floaters receive, the more noticeable they become; the brain adapts faster when they are not being monitored.

These are sensible suggestions from eye professionals rather than proven treatments. There is no evidence that eye exercises, drinking more water, massage, diet or blue-light filters make floaters go away.

If floaters are making you anxious or low in mood, it is worth saying so. Knowing the retina is healthy helps many people, and some benefit from talking with their GP.

What treatments are still being researched?

Researchers are exploring ways to break up floaters without surgery. One approach injects tiny particles into the eye that attach to floater clumps; a gentle laser then produces microscopic bubbles that break the clumps apart. It has worked in rabbits and in samples of human vitreous removed at surgery, but has not been tested in people. Drugs that liquefy or loosen the vitreous have been studied for other conditions, but are not used for floaters and can themselves cause new floaters. None of these is available as a treatment.

When are laser or surgery worth considering?

If floaters are still interfering with reading, driving or work after several months, a procedure may be worth discussing. YAG laser for floaters can help selected people with a single, well-defined floater positioned safely away from the lens and retina. A randomised trial found it improved symptoms compared with a sham treatment in people with a ring-shaped floater.

Weiss ringDiffuse strands
A single, well-defined ring (left) is a different problem from a diffuse web of strands (right). Laser suits some well-defined floaters; widespread strands usually do not suit laser.

For floaters that remain troublesome despite time, vitrectomy removes the gel and the floaters within it. It is effective but carries real risks, including an earlier cataract and a small risk of retinal detachment. The page on floaters and floater surgery explains how the options are weighed, and the article on recovery after vitrectomy for floaters describes what surgery involves afterwards.

Other questions about non-surgical floater treatment

Is VitroCap N safe?

Its ingredients are common nutrients at modest doses, and it is listed with the TGA as a low-risk complementary medicine. The published trial did not report on side effects. If you take other medicines or supplements, particularly zinc or high-dose vitamins, check with your pharmacist or GP before adding it.

My optometrist recommended VitroCap N. Should I take it?

It is a reasonable thing to try if you want to and are comfortable with the cost, as long as you understand the evidence is weak. Make sure your retina has been examined first, and do not let it delay urgent assessment if your symptoms change.

How long would it take to know if VitroCap N is working?

The trial ran for six months, and the distributor recommends at least three to six months. Because floaters often improve over that period anyway, it is hard to tell whether any change is due to the supplement.

Can I get low-dose atropine drops in Australia?

Only on prescription. Low-dose atropine is registered in Australia for slowing myopia in children, so an eye doctor would need to prescribe it off-label for floaters, after checking that your eye's drainage angle is not narrow.

Do floaters ever disappear completely?

Sometimes, but more often they become less noticeable rather than vanishing. They settle lower in the eye, out of the main line of sight, and the brain learns to ignore them.

Where can I read more?

When do floaters need urgent attention?

No supplement, drop or waiting period is appropriate for new symptoms that could mean a retinal tear. About one in seven people who develop a sudden burst of floaters or flashes has a retinal tear at their first examination. Contact your ophthalmologist urgently, or attend an emergency department, if you notice:

  • a sudden shower of new floaters
  • new flashes of light
  • a shadow or curtain spreading across your vision
  • a sudden drop in vision

The article on flashes, floaters or a curtain in your vision explains these warning signs in more detail.

References

  1. Ankamah E, et al. Dietary intervention with a targeted micronutrient formulation reduces the visual discomfort associated with vitreous degeneration . Translational Vision Science & Technology. 2021;10(12):19.
  2. Therapeutic Goods Administration. VitroCap N, ARTG 437521 . Australian Register of Therapeutic Goods. Accessed September 2026.
  3. Stiltec Global. VitroCap N product information . Accessed September 2026.
  4. Du J, et al. Low-dose 0.01% atropine eye drops for symptomatic vitreous floaters: a noninvasive, safe, and effective therapeutic option . Journal of VitreoRetinal Diseases. 2025;9(6):831–835.
  5. ClinicalTrials.gov. Low dose atropine for symptomatic vitreous floaters (NCT06174935) . Accessed September 2026.
  6. Yam JC, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control . Ophthalmology. 2019;126:113–124.
  7. Kaymak H, et al. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects . Graefe's Archive for Clinical and Experimental Ophthalmology. 2018;256:2211–2217.
  8. Therapeutic Goods Administration. Eikance (atropine sulfate) prescription medicine registration . Accessed September 2026.
  9. Harmer SW, Luff AJ, Gini G. Optical scattering from vitreous floaters . Bioelectromagnetics. 2022;43:90–105.
  10. Serpetopoulos CN, Korakitis RA. An optical explanation of the entoptic phenomenon of 'clouds' in posterior vitreous detachment . Ophthalmic and Physiological Optics. 1998;18:446–451.
  11. Milston R, Madigan MC, Sebag J. Vitreous floaters: etiology, diagnostics, and management . Survey of Ophthalmology. 2016;61:211–227.
  12. Ma JW, et al. A new pharmacological vitreolysis through the supplement of mixed fruit enzymes for patients with ocular floaters or vitreous hemorrhage-induced floaters . Journal of Clinical Medicine. 2022;11:6710.
  13. Hammer M, et al. Forward light scattering of the vitreous gel after enzymatic aging: an in vitro model to study vitreous opacification . Investigative Ophthalmology & Visual Science. 2024;65(3):36.
  14. Sauvage F, et al. Laser-induced nanobubbles safely ablate vitreous opacities in vivo . Nature Nanotechnology. 2022;17:552–559.
  15. Shah CP, Heier JS. YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters: a randomized clinical trial . JAMA Ophthalmology. 2017;135:918–923.
  16. Wagle AM, et al. Utility values associated with vitreous floaters . American Journal of Ophthalmology. 2011;152:60–65.
  17. Gouliopoulos N, et al. The association of symptomatic vitreous floaters with depression and anxiety . International Ophthalmology. 2024;44:218.
  18. Hollands H, et al. Acute-onset floaters and flashes: is this patient at risk for retinal detachment? JAMA. 2009;302:2243–2249.
  19. Moorfields Eye Hospital NHS Foundation Trust. Flashes and floaters . Patient information. Accessed September 2026.
  20. US Food and Drug Administration. What you should know about eye drops . Accessed September 2026.
  21. Chen S, Hodge C. Degenerative floaters: a practical review for optometrists. mivision. October 2018.

How can we help?

Searches the English information on this website.

Dr Simon Chen practices at

Vision Eye Institute

Level 3, 270 Victoria Avenue
Chatswood NSW 2067
Call 02 9424 9999Get directions
Map showing Vision Eye Institute Chatswood at 270 Victoria AvenueOpen interactive Google Maps